Alector Inc ALEC

$1.83 0.00 (—)

Valuation

Market cap
208,799,000
Revenue TTM
$21,050,000
Net income TTM
$-142,930,000
PE ratio
0.00
Forward PE
—
Profit margin
-679.00%
Debt to equity
-0.99

Trading

Volume
1,108,442
Avg volume
3,684,738
Day's range
$1.72 – $1.84
Shares out
111,657,000
Stochastic %K
20%
Beta
0.62
Analysts
Sell
Price target
$3.90

Price

Company profile

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL0...

Show more

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 231 5660
Website
https://www.alector.com
Address
131 Oyster Point Boulevard, Suite 600, South San Francisco, United States

Latest news

Stocktwits

keywestbitcoin Oct 22, 4:48 PM
$ALEC i re-entered at 1.76, easy
1 replies
Cornlikker Oct 21, 10:59 AM
$ALEC Show me that $8.00+ again biotech biotch!!!
0 replies
Chi2ggzz Oct 21, 3:09 AM
$ALEC 1.75 been holding strong here, might have to start nibbling here
1 replies
CC123italy Oct 20, 9:08 PM
$ALEC extremely bullish
0 replies
bizness1957 Oct 19, 3:28 PM
$ALEC Alector, Inc. (Nasdaq: ALEC) has approximately $223.7 million in cash, cash equivalents, and marketable securities following its recent $100 million upfront licensing deal with Genentech and a subsequent follow-on/underwritten equity offering.
0 replies
Jobsworth Oct 19, 12:07 PM
$ALEC seeing shares for sale PM at $26 on level 2. First time in a while. I guess someone knows something 🚀👌🔥⬆️✅
0 replies
VintageCrow Oct 18, 5:16 PM
$ALEC $GP.X $RCT If you are wondering which ticker will get sent next week? Make sure to put UPLD on your watch. Look below why I am bullish on UPLD, it's a rare setup that has the potential to go parabolic! UPLD: ✅ 2M float! ✅ Cash on hand 38M. ✅ $20 Intrinsic value. ✅ Cash/sh: $10.71 ✅13B market opportunity! Enjoy your Sunday!
0 replies
focafoca99 Oct 16, 9:02 PM
$ALEC targeted a $75.0M equity offering of 36.6M shares at $2.05 each, expected to close Oct 19.
0 replies